Sacituzumab govitecan receives FDA approval for TNBC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Sacituzumab govitecan was granted regular FDA approval for patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, at least one of them for metastatic disease.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login